In the eastern Democratic Republic of the Congo, where the Bundibugyo strain of Ebola has taken at least 4,000 lives since May, science is attempting what containment alone cannot achieve: stopping the virus inside those who have already been touched by it. Researchers and medical workers have begun enrolling exposed but still-healthy individuals in a clinical trial of obeldesivir, an antiviral pill with no approved predecessor for this particular strain. The trial is both a race against an outbreak that has spread across seven provinces and a quiet act of hope — that medicine, given early eno
DR Congo launches trial of experimental Ebola prevention drug amid outbreak
At least 4,000 deaths recorded from the Bundibugyo Ebola outbreak in eastern DR Congo since mid-May 2026.
A strain for which no approved vaccine or treatment yet exists
Mark
So they're giving this drug to people who've been exposed but don't have symptoms yet. How do they even know who's been exposed?
Mimi
They're focusing on people with documented contact — healthcare workers treating patients, family members in the home. Those are the clearest cases. But you're right that it's hard to track everyone who might have been exposed.
Luke
The source says tracking is "difficult in the country." That's vague. We don't know if it's a logistics problem, a testing problem, or something else. And 250 enrolled so far toward a goal of 1,000 — we don't know the timeline for reaching that.
Mark
Why is there no vaccine for this particular virus if there's one for other Ebola strains?
Mimi
The Bundibugyo virus is a different strain. Ervebo, the vaccine they're using, was developed for other Ebola types. They're studying whether it works here, but it's not proven yet.
Luke
Right — so they have a vaccine that might work, but they don't know. And they have a drug that might work, but they don't know. That's the actual situation.
Mark
What happens to someone in the trial if they start showing symptoms?
Mimi
They get immediate supportive care. That's the treatment available right now — managing the symptoms while the body fights the virus.
Luke
The source says supportive care is "beneficial when symptoms are detected early." That's true, but it's not a cure. We should be clear about what supportive care actually means — fluids, blood transfusions, organ support — and that it's still not a guarantee.
Mark
How long until we know if this drug actually works?
Mimi
The trial runs 42 days per participant, but with 1,000 people enrolling over time, results will take months. Probably not until well into next year.
Luke
We don't have a timeline from the source. We're inferring. And we don't know how many cases they need to see in the placebo group to have statistical power. That matters for whether the trial can actually answer the question.
The Pulse
- The Bundibugyo Ebola outbreak has killed at least 4,000 people across seven provinces since mid-May, and no approved vaccine or treatment exists for this specific strain.
- The virus is spreading faster than authorities can track it, made harder by the fact that infected people show no symptoms — and cannot transmit the disease — during the very window when they are hardest to identify.
- Over 250 people in Ituri province, including healthcare workers and family members of patients, have already enrolled in the EBO-PEP trial, with nearly 1,000 participants ultimately targeted.
- Each enrollee — exposed within five days but not yet symptomatic — will receive either obeldesivir or a placebo, then be monitored daily for three weeks to determine whether the drug can halt the disease before it begins.
- If obeldesivir proves effective, it could become the first post-exposure prevention tool for Bundibugyo virus, reshaping how future outbreaks of this strain are managed.
In the eastern Democratic Republic of the Congo, where the Bundibugyo strain of Ebola has taken at least 4,000 lives since May, science is attempting what containment alone cannot achieve: stopping the virus inside those who have already been touched by it. Researchers and medical workers have begun enrolling exposed but still-healthy individuals in a clinical trial of obeldesivir, an antiviral pill with no approved predecessor for this particular strain. The trial is both a race against an outbreak that has spread across seven provinces and a quiet act of hope — that medicine, given early enough, might interrupt the path from exposure to death.
In eastern DR Congo, where the Bundibugyo strain of Ebola has killed at least 4,000 people since mid-May and spread across seven provinces, researchers have begun one of the few proactive interventions available: testing whether an experimental antiviral pill can prevent the disease from developing in people who have already been exposed. More than 250 residents of Rwampara have enrolled in the trial, which began in July in Ituri province — the outbreak's epicenter.
The study, called EBO-PEP and coordinated by the medical nonprofit ALIMA, is built around post-exposure prophylaxis — the idea of giving a drug called obeldesivir, made by Gilead, to people who have had contact with a confirmed Ebola patient within the previous five days but have not yet shown symptoms. The trial aims to enroll nearly 1,000 adults and children aged 12 and older, with half receiving a placebo so researchers can measure the drug's true effect. Participants include healthcare workers and family members — those most likely to have been exposed.
Each participant will be seen in person every day for three weeks, with a final follow-up call at day 42. If symptoms emerge at any point, immediate supportive care will be provided. The daily monitoring is itself a critical safeguard, since early detection dramatically improves survival odds.
The broader outbreak has recorded at least 8,300 confirmed cases, and the scale has overwhelmed conventional tracking and isolation efforts. While Ervebo — a vaccine effective against other Ebola strains — has been deployed for healthcare workers, its effectiveness against Bundibugyo remains unproven. Obeldesivir takes a different approach entirely, aiming not to prevent initial infection but to stop the virus from replicating once exposure has occurred. Results are months away, but they may determine whether post-exposure prophylaxis becomes a lasting part of the response to this and future outbreaks of the Bundibugyo strain.
In the eastern Democratic Republic of the Congo, where an Ebola outbreak has claimed at least 4,000 lives since mid-May, researchers have begun testing whether an experimental antiviral pill can stop the disease before it takes hold. More than 250 people in Rwampara have enrolled in a clinical trial of obeldesivir, a drug made by Gilead that targets the Bundibugyo virus — a strain for which no approved vaccine or treatment yet exists. The study, which started in July in Ituri province at the outbreak's epicenter, represents one of the few tools available to prevent infection in a region where the virus continues to spread faster than containment efforts can manage.
The trial, called EBO-PEP and coordinated by the medical nonprofit ALIMA, is testing what's known as post-exposure prophylaxis — giving the drug shortly after someone has been exposed to the virus to see whether it can prevent the disease from developing at all. The study aims to enroll nearly 1,000 adults and children aged 12 and older who have had contact with a confirmed Ebola case within the previous five days but show no symptoms yet. Half of the participants will receive a placebo, allowing researchers to measure whether the drug actually works.
The participants include healthcare workers and family members of patients — people at the highest risk of exposure. According to physician Godefroy Bassari, each person will be monitored in person every day for three weeks, with a final check-in by phone at day 42. If anyone develops symptoms during that time, they will immediately receive supportive care. ALIMA emphasized that early detection and treatment significantly improve outcomes, making the daily monitoring a critical part of the study design.
The Bundibugyo outbreak has spread across seven provinces in eastern DR Congo, with at least 8,300 confirmed cases recorded since the declaration in mid-May. The sheer scale of the outbreak has outpaced the ability of authorities to track and isolate new cases — a particular challenge because Ebola only spreads once symptoms appear, making it difficult to identify and quarantine people who may be silently incubating the virus. The country has begun vaccinating healthcare workers with Ervebo, a vaccine that proved effective against other Ebola strains in previous outbreaks, but its effectiveness against the Bundibugyo virus remains under study.
Obeldesivir represents a different approach: rather than preventing infection through vaccination, it aims to interrupt the virus's ability to replicate once exposure has occurred. If the trial shows the drug can prevent disease in people who have been exposed but not yet symptomatic, it could become a crucial tool for protecting healthcare workers and family members caring for patients. The results will likely take months to emerge, but they may determine whether post-exposure prophylaxis becomes part of the response to future outbreaks of this particular strain.
Notable Quotes
Participants will be monitored in person daily for 21 days, with a final phone call on day 42. If a participant develops symptoms, they will immediately receive supportive care.— Physician Godefroy Bassari
Want the full story?
Read the original at UA.NEWS ↗
Health & Medicine